Navigation Links
Adaptive TCR Launches the immunoSEQ™ Product Line - Visualizing the Immune System With Next-Generation Sequencing.
Date:10/20/2010

SEATTLE, Oct. 20 /PRNewswire/ -- Adaptive TCR Technologies, a biotech firm based in Seattle, WA, announced today the release of its immunoSEQ™ profiling service and immunoSEQ Analyzer™ bioinformatics software platform.  Together, these tools provide researchers and clinicians the ability to profile and monitor the adaptive immune system at a level of detail that has never before been possible.

"ImmunoSEQ represents one of the first specific applications of next-generation sequencing technology," offers Chad Robins, CEO and Founder of Adaptive TCR. "We have delivered the Hubble Telescope as compared to a pair of binoculars to look at the adaptive immune system."

ImmunoSEQ assays use proprietary chemistry to amplify the rearranged CDR3 regions of T-cell receptor (TCR) genes responsible for most TCR diversity.  Each immunoSEQ assay can generate millions of cell-specific sequences, allowing a remarkably deep characterization of the T-cell repertoire in any sample.  To analyze this large amount of data, Adaptive TCR provides access to the immunoSEQ Analyzer, a bioinformatics software platform comprising a suite of tools designed specifically to handle immunoSEQ data.  

"Using DNA sequencing to look at cells of the immune system is particularly powerful," said Dr. Harlan Robins, a computational biologist at the Fred Hutchinson Cancer Research Center and co- founder of Adaptive TCR. "By bringing together unique amplification chemistries, massively parallel sequencing and powerful, user-friendly software, we are providing access to the adaptive immune system in unbelievable detail."  

In addition to providing information on the basic functioning of the immune system, immunoSEQ data can contribute to the understanding and development of many important medical conditions and applications, including cancer immunotherapy, autoimmune disorders, vaccine development, and infectious disease.  "We know that T cells are involved in autoimmune diseases like Type 1 Diabetes, Multiple Sclerosis, Rheumatoid Arthritis and others," noted Dr. Christopher Carlson, an investigator at the Fred Hutchinson Cancer Research Center and a co-founder of Adaptive TCR.  "Now we can examine what's going on in incredible detail, and hopefully we will find tests based on T-cell repertoires that give physicians prognostic information and treatment guidance."

ImmunoSEQ assays and the immunoSEQ Analyzer are easily available to any researcher.  The researcher or clinician need only provide a DNA sample; the company does all the laboratory work, and uploads the resulting sequence data to a secure web site that is available to the researcher at all times. "The true value to our clients lies in the combination of the assay with a user-friendly, powerful software suite for data analysis, visualization, and interpretation," adds CEO Robins.  

Robins believes that the industry is at the very beginning, "as our technology becomes increasingly powerful, we look forward to witnessing clients using immunoSEQ to answer fundamental questions in the field of adaptive immunity, leading to a better quality of life for people afflicted with dysfunctional immune systems."

About Adaptive TCR Corporation

Adaptive TCR Corporation, headquartered in Seattle, WA, develops, commercializes and supports online solutions for large scale immune system profiling. Adaptive TCR's proprietary technologies were developed at the Fred Hutchinson Cancer Research Center by co-founders Harlan Robins, PhD and Chris Carlson, PhD. The technologies include a DNA amplification chemistry that can generate many millions of T cell receptor sequences from a single DNA sample, and a bioinformatics software suite designed specifically to manage the large amounts of data resulting from a typical assay. These technologies are marketed for life science research applications under the brand name immunoSEQ™ and immunoSEQ Analyzer™. The company began commercial operations in 2009 under the leadership of Chad Robins, CEO.


'/>"/>
SOURCE Adaptive TCR Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies
2. ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials"
3. Truman Medical Centers Becomes One of the First Hospitals in the U.S. To Install the Worlds First Adaptive 128-slice CT Scanner
4. Prometheus Research Launches Solutions Group to Springboard HTSQL-based Solutions for Customers
5. Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinsons Disease
6. CoreLab Partners Launches New DXA Imaging Service Offerings
7. Verenium Launches DELTAZYM® GA L-E5 Enzyme for Fuel Ethanol Production
8. InSightec Launches ExAblate(R) One and ExAblate(R) OR Systems at CIRSE 2010
9. Michael J. Fox Foundation Launches Parkinsons Progression Markers Initiative (PPMI)
10. HelixLife Launches Custom Health Supplements, Anti-Aging and Acne Skin Serums
11. Norgen Biotek Corp. Launches a Novel kit to Collect, Concentrate, Preserve and Isolate DNA, RNA, microRNA and proteins from Urine Specimens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 2016 The report "Biochips ... Gene Expression) Lab-on-a-chip (IVD & POC, Proteomics), ... Centers), Fabrication Technology (Microarrays, Microfluidics) - Forecast ... is expected to reach USD 17.75 Billion ... 2015, growing at a CAGR of 18.4% ...
(Date:5/3/2016)... ... May 03, 2016 , ... Flagship Biosciences, the ... Gillett to its Board of Directors. Dr. Gillett recently retired from Charles River ... President and Chief Scientific Officer. A board-certified veterinary pathologist, Dr. Gillett joined Charles ...
(Date:5/3/2016)... Texas , May 3, 2016  Dr. ... plastic surgeon in The Woodlands, Texas ... destroys 24 percent of treated fat cells in just ... woman. Close to 90 percent of Americans report feeling ... options. Nonsurgical fat reduction procedures are a growing industry. ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... its clients in mind, the fresh look and added functionality give the agricultural ... years have seen a dynamic shift in agriculture – from precision farming via ...
Breaking Biology Technology:
(Date:3/11/2016)... 2016 http://www.apimages.com ) - --> ... available at AP Images ( http://www.apimages.com ) - ... to produce the new refugee identity cards. DERMALOG will be unveiling ... in Hanover next week.   --> ... used to produce the new refugee identity cards. DERMALOG will be ...
(Date:3/9/2016)... -- This BCC Research report provides an overview of ... (RNA Seq) market for the years 2015, 2016 and ... data analysis, and services. Use this report ... such as RNA-Sequencing tools and reagents, RNA-Sequencing data analysis, ... segment and forecast their market growth, future trends and ...
(Date:3/3/2016)... -- FlexTech, a SEMI Strategic Association Partner, awarded five FLEXI ... Leadership in Education, and, in a category new this ... year of the FLEXI Awards and the winners join ... past years . Judging was done on a set ... by a panel of non-affiliated, independent, industry experts. ...
Breaking Biology News(10 mins):